Clovis Oncology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Clovis Oncology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 23.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clovis Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2022 | 133 | -252 | -176 | -176 | N/A |
| 6/30/2022 | 140 | -263 | -181 | -181 | N/A |
| 3/31/2022 | 145 | -258 | -193 | -193 | N/A |
| 12/31/2021 | 149 | -265 | -196 | -196 | N/A |
| 9/30/2021 | 156 | -299 | -211 | -211 | N/A |
| 6/30/2021 | 157 | -310 | -219 | -219 | N/A |
| 3/31/2021 | 160 | -336 | -241 | -232 | N/A |
| 12/31/2020 | 165 | -369 | -261 | -253 | N/A |
| 9/30/2020 | 161 | -370 | -275 | -267 | N/A |
| 6/30/2020 | 159 | -385 | -279 | -269 | N/A |
| 3/31/2020 | 152 | -413 | -311 | -308 | N/A |
| 12/31/2019 | 143 | -400 | -343 | -324 | N/A |
| 9/30/2019 | 134 | -400 | -356 | -336 | N/A |
| 6/30/2019 | 119 | -396 | -376 | -352 | N/A |
| 3/31/2019 | 110 | -377 | -444 | -364 | N/A |
| 12/31/2018 | 95 | -368 | -430 | -366 | N/A |
| 9/30/2018 | 82 | -321 | -412 | -349 | N/A |
| 6/30/2018 | 76 | -291 | -380 | -322 | N/A |
| 3/31/2018 | 67 | -366 | -282 | -281 | N/A |
| 12/31/2017 | 56 | -346 | -265 | -261 | N/A |
| 9/30/2017 | 39 | -365 | -254 | -250 | N/A |
| 6/30/2017 | 22 | -370 | -268 | -265 | N/A |
| 3/31/2017 | 7 | -324 | -267 | -263 | N/A |
| 12/31/2016 | 0 | -349 | -267 | -267 | N/A |
| 9/30/2016 | N/A | -398 | -290 | -288 | N/A |
| 6/30/2016 | N/A | -431 | N/A | -299 | N/A |
| 3/31/2016 | N/A | -373 | N/A | -288 | N/A |
| 12/31/2015 | N/A | -353 | N/A | -253 | N/A |
| 9/30/2015 | N/A | -288 | N/A | -211 | N/A |
| 6/30/2015 | N/A | -229 | N/A | -174 | N/A |
| 3/31/2015 | N/A | -192 | N/A | -146 | N/A |
| 12/31/2014 | 14 | -160 | N/A | -117 | N/A |
| 9/30/2014 | 14 | -134 | N/A | -107 | N/A |
| 6/30/2014 | 14 | -115 | N/A | -88 | N/A |
| 3/31/2014 | 14 | -100 | N/A | -77 | N/A |
| 12/31/2013 | N/A | -85 | N/A | -72 | N/A |
| 9/30/2013 | N/A | -76 | N/A | -67 | N/A |
| 6/30/2013 | N/A | -74 | N/A | -65 | N/A |
| 3/31/2013 | N/A | -71 | N/A | -61 | N/A |
| 12/31/2012 | N/A | -74 | N/A | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CLVS.Q's forecast earnings growth is above the savings rate (2.1%).
Earnings vs Market: Insufficient data to determine if CLVS.Q's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CLVS.Q's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CLVS.Q's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CLVS.Q's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLVS.Q's Return on Equity is forecast to be high in 3 years time